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Albumin JafTna is an el~trop~om~~~y slowly moving genetic variant of human serum albumin found in two members 
of a Tamil family from Jaffna (Northern Sri Lanka), both heteroxygous for the abnormal protein. Sequential analysis 
of albumin Jai&a, purified from serum by ion exchange ~~o~to~phy on DEAE Sephadex and Mono Q columns, 
revealed that this variant is a new abnormal proalbumin, arising from a -1 Arg-+Leu substitution, which prevents the 
proteolytic remoyal of the N-terminal hexapeptide and allows the mutated proalb~n to enter the ~rculation. The pres- 
ence of two additional positive charges is in keeping with the decreased electrophoretic mobility of albumin Jaffna, as 
well as with its isoelectric point of 5.01, determined by chromatof~ing on a Mono P column. The variant is selectively 
cleaved by trypsin in vitro, leaving leucine -1 as N-terminal residue. 
Proalbumin; Genetic variant; N-terminal sequence; Chromatofocusing; Isoelectric point 
1. INTRODUCTION 
Albumin is synthesized by the liver cells in the 
form of a precursor, proalbumin [1], which has an 
additional highly basic hexapeptide Arg-Gly-Val- 
Phe-Arg-Arg attached at its N-terminal end [2]. 
This leader peptide is removed by a proteolytic 
event in the Golgi complex just before the protein 
enters the circulation [3]. Although the mam- 
malian proalbumin converting enzyme has not yet 
been isolated, recent findings point to the role of 
a calcium dependent KEXZlike protease found in 
hepatic secretory vesicles [4,5]. However, a critical 
requirement for the excision of the propeptide is 
the presence of the Arg-Arg sequence at the 
cleavage site in the precursor molecule. In fact the 
substitution of one of this pair of basic residues 
prevents the proteolytic removal of the mutated 
propeptide, as demonstrated by the existence of 
circulating variants, pro~bumin Christchurch ( - 1 
Arg - Gln) 161, proalbumin Lille (- 2 Arg --+ 
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His) [7] and proalbumin Takefu (- 1 Arg - Pro) 
PI. 
In a continuing structural study of genetic 
variants of human serum albumin, we have 
established that albumin Jaffna, a genetic variant 
found in a 60 year old man, a Tamil from Jaffna 
(Northern Sri Lanka) [9] is a new type of pro- 
albumin, arising from a - 1 Arg - Leu substitu- 
tion. The molecule shows the same susceptibility to 
limited tryptic cleavage as pro~bu~ns Christ- 
church and Lille [7,10], but differs with respect o 
the great instability of its N-terminal hexapeptide. 
2. MATERIALS AND METHODS 
2.1. Albumin purification 
A 4 ml serum sample was dialyzed against 0.11 M phosphate 
buffer, pH 5.75 and chromatographed on a DEAE Sephadex 
column (1.3 x 100 cm) eluted with the same buffer [l I]. The 
fractions containing albumin were pooled, concentrated and 
desalted on an Amicon apparatus equipped with a PM-30 
membrane. 
Further puri~~tion of albumin Jaffna was achieved by 
anion exchange chromatography using the Pharmacia FPLC 
system equipped with a mono Q (HR 5/S) column developed 
with a linear gradient of O-200 mM NaCl in 20 mM 
piperazine*HCl buffer, pH 5.8. 
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The material eluted under each peak was desahed by gel 
filtration on a PD 10 column. 
2.2. Structural studies 
Amino acid analyses were carried out by ion exchange 
chromatography with post column ninhydrin derivatization ac- 
cording to Moore [12] on a Kontron Chromakon 500 automatic 
analyzer. N-terminal residues were identified as dansyl 
derivatives according to Hartley [13]. Automated sequence 
analysis was performed in a Beckman 890 M spinning cup li- 
quid phase sequenator using the fast protein Quadrol program 
with precycled polybrene. The PTH amino acid derivatives were 
identified by RP-HPLC on a Beckman Ultrasphere ODS col- 
umn according to Pucci et al. [14]. 
2.3. Screening of CNBr fragments 
Whole reduced slow and normal albumins were carboxy- 
methylated and cleaved with CNBr as previously reported 1151. 
The fragments were analysed by polyacrylamide gel isoelectric 
focusing performed in the presence of 8 M urea in the pH inter- 
val 2.5-8 [16]. 
2.4. Chromatofocusing 
The isoelectric points were determined by chromatofocusing 
on a mono P column HR 5120 on the Pharmacia FPLC System 
according to Hutchinson and Matejtschuk 1171. 
2.5. Limited tryptic digestion 
The conditions for tryptic hydrolysis were essentially those of 
Quinn et al. 121. After digestion for 1 h at 37”C, the mixture 
was equilibrated in 20 mM piperazine . HCl buffer, pH 5.8, on 
a PD 10 column and resolved on mono Q column as described 
in section 2.1. 
3. RESULTS AND DISCUSSION 
Normal and Jaffna albumins have been purified 
by ion exchange chromatography (fig.1) and, as 
expected on the basis of the electrophoretic 
behaviour [9], the variant elutes ahead of the nor- 
mal protein. The serum content in the two proteins 
is unequal, the variant accounting for about one 
third of the total ~bumin amount, The proteins 
were assayed for homogeneity by SDS gel elec- 
trophoresis which shows in both cases the presence 
of a single band with a molecular weight approx- 
imately equal to that of normal albumin (66500). 
Their amino acid composition reveals that the slow 
variant differs from the normal protein by its 
higher arginine, glycine, valine, phenylalanine and 
leucine content. While the N-terminal residue of 
normal albumin is aspartic acid, in the peak of the 
abnormal protein we found 3 different amino 
acids: arginine, phenylalanine and aspartic acid. 
We therefore resolved peak J by anion exchange 
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Fig.1. Chromatograp~c separation of normal (N) and Jaffna 
(J) albumins on a DEAE Sephadex column eluted with 0.11 M 
phosphate buffer, pH 5.75. 
3 components, 1, 2 and 3. These fractions account 
respectively for 40070, 15% and 45% of the total 
protein content and are characterized by the N- 
terminal residues arginine, phenylalanine and 
aspartic acid. They were subsequently submitted to 
automatic sequence analysis for 10 cycles yielding 
the single N-terminal portion of normal albumin in 
the case of fraction 3 and a different primary struc- 
ture, together with a background of the normal se- 
quence, in the other two cases. The predominant 
component of peak 1 gave ~g-sly-V~-Phe-~g- 
Leu-Asp-Val-His-Lys, while that of peak 2 gave 
Phe-~g-Leu-Asp-~a-His-Lys-Ser-flu-V~. From 
these data we conclude that albumin Jaffna is a 
Volume ml 
2’5 
Fig.2. FPLC of the components of peak J from the DEAE 
Sephadex chromatography on a mono Q column. Elution was 
performed by a linear gradient of O-200 mM NaCl in 20 mM 
piperazine+HCl buffer, pH 5.8. Flow rate: 1 ml/min. 
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new proalbumin variant arising from a - 1 Arg 
- Leu substitution, which prevents the cleavage 
of the propeptide and allows the proalbumin to 
leave the liver cell intact. 
Jaffna and normal albumin have been submit- 
ted to comparative analysis of the CNBr fragments 
by isoelectric focusing in the presence of 8 M urea 
(fig.3). The only fragment which behaves different 
in the twa samples is CNBr I which in the case of 
the Jaffna variant focuses closer to the cathode 
than the normal counterpart (Apl = +0.25 pH 
units). This result shows that the molecular abnor- 
mality of this variant is only located in this frag- 
ment and that the rest of the albumin molecule is 
unaffected by chemical or proteolytic cleavage. 
In order to further characterize the fractions and 
determine their isoelectric point, we also separated 
the components of peak J from the DEAE- 







Fig.3. Isoelectric focusing of CNBr fragments from normal 
(lane 1) and Jaffna (lane 2) albumins. Peptides were resolved in 
the pH range 2.5-8 in the presence of 8 M urea. CNBr 
fragments are numbered according to their order in the known 
sequence of human serum albumin [19]. Each fragment, except 
the C-terminal CNBr VII, may have two charge forms, owing 
to the homoserine-homo~~ne Iactone equilibrium. 
Microheterogeneity, mostly in the case of larger fragments, is 
probably due either to partial cleavage or oxidation of 
unreacted cysteines or deamidation. The arrow on the right 
Fig.4. FPLC analysis of the components of peak J from the 
DEAE Sephadex chro~tography (fig.2) by chromatof~using 
on a mono P column. Aliquots (1 ml) of the mixture (1 n&ml) 
in piperaaine~HC1 buffer (25 mM, pH 6.3) were applied to the 
mono P column equilibrated with this buffer. Elution was 
performed at 1 ml/min with Polybuffer 74 diluted 1: 10 (v/v) 
in water (UHQ, Elgastad) which had been brought to pH 4.5 
marks the abnormal CNBr I fragment. with HCl [17]. 
P column, under the conditions described by Hut- 
chinson and Matejtschuk [17]. The elution profile 
(fig.4) shows the presence of 3 peaks, with an 
isoelectric point of 5.01,4.90 and 4.80, accounting 
for 40070, 15% and 45% of the total albumin con- 
tent, which correspond to albumin Jaffna, the N- 
terminal phenylalanine form and normal albumin 
respectively. The isoelectric point of albumin Jaff- 
na (5.01) is identical with that of proalbumins of 
the Christchurch type, while it is lower than that of 
proalbumins of the Lille type (5.06) obtained 
under the same conditions. The presence of two 
additional positive charges in the propeptide of the 
variant matches the isoelectric point of both the 
native protein and its CNBr I fragment, as well as 
the electrophoretic mobility on cellulose acetate 
f91. 
As susceptibility to limited tryptic cleavage in 
vitro is a characteristic of other pro~bumins, such 
as Christchurch [lo] and Lille 171, we submitted 
albumin Jaffna to tryptic digestion under the con- 
ditions described by Quinn et al. [2]. This induced 
a complete change in the chromatographic be- 
haviour on Mono Q, with the retention time 
beco~ng identical to that of normal serum 
albumin (fig.5). After this cleavage no significant 
changes of molecular weight were observed, while 
N-terminal amino acid analysis identified in the 
variant a leucine residue instead of the aspartic 
acid found in normal albumin. When the limited 
tryptic digestion was performed on the DEAE- 
Sephadex peak J, we observed the complete disap- 
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Fig.5. Limited tryptic digestion of proalbumin Jaffna. Purified 
albumin Jaffna was incubated with trypsin (1:5000, w/w) in 
50 mM KzHPO~.HCI buffer, pH 7.5, 50~M CaCl2 at 37”C, 
and digestion was stopped with soybean trypsin inhibitor [Z]. 
The digests (0 h (A); 1 h (B)) were resolved by FPLC on a Mono 
Q column under the conditions described in fig.2 The same 
results were obtained when the digestion was performed on the 
components of peak J from the DEAE Sephadex 
chromatography (0 h (fig.2); 1 h (B)). 
pearance of the first two peaks which were con- 
verted into the species with N-terminal leucine that 
coelutes with normal albumin (fig.5). These data 
show that albumin Jaffna, as well as the form with 
N-terminal phenylalanine, is selectively cleaved by 
trypsin after arginine - 2, leaving leucine - I as 
the N-terminal residue. This result differs from the 
findings of Tillyer et al. obtained under slightly 
different conditions [ 181. 
The - 1 Arg -3 Leu substitution found in the 
variant can be accounted for by a single base muta- 
tion in the structural gene: codon - 1, CGA in nor- 
mal proalbumin [19], must be changed to CTA 
encoding for leucine. Albumin Jaffna is the third 
variant substituted in this position: thus, 3 of the 
4 possible single base changes in codon - 1, which 
would result in detectable abnormalities, have been 
so far observed. They all occur in the second posi- 
tion of this codon. Further studies will be required 
to establish whether the apparent clustering of the 
mutations in the Arg-Arg sequence of the propep- 
tide reflects the existence of h~e~utable sites in 
the albumin gene or is instead due to the relative 
ease of identifying proalbumin variants. The net 
increase of at least two positive charges due to the 
presence of the propeptide, which is likely exposed 
to the solvent, could make these variants more 
easily detectable than others. 
Although it has been reported that all the pro- 
albumins are somewhat unstable, probably 
because the propeptide may be cleaved by one of 
the many serine proteases present in serum [8], the 
Jaffna variant is particularly labile: upon storage 
for two months at 4°C the initially nearly equal 
amount of the two albumins in fresh serum 
changes to 14% Jaffna and 86% normal [9]. This 
agrees with the proportion of albumin Jaffna com- 
pared with normal (1: 2) that we found after the 
DEAF Sephadex chromatography performed on a 
serum sample stored for a long period. This 
purification step allowed us to obtain the variant 
proalbumin in a homogeneous and stable form in 
all cases so far examined in our laboratory, i.e. 
albumin Pollibauer 1201 and several samples of the 
Lille and Christchurch type. Thus it is likely that 
albumin Jaffna, even after this isolation pro- 
cedure, may undergo degradative processes, giving 
rise to both the N-terminal phenylalanine form and 
the normal protein. It is unclear whether this is due 
to a proteolytic cleavage or reflects a chemical in- 
stability of the N-terminal propeptide of this 
variant. 
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